Abrogation of Marek's disease virus replication using CRISPR/Cas9

被引:19
|
作者
Hagag, Ibrahim T. [1 ,2 ]
Wight, Darren J. [1 ]
Bartsch, Denise [3 ]
Sid, Hicham [3 ]
Jordan, Ingo [4 ]
Bertzbach, Luca D. [1 ]
Schusser, Benjamin [3 ]
Kaufer, Benedikt B. [1 ]
机构
[1] Free Univ Berlin, Inst Virol, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany
[2] Zagazig Univ, Dept Virol, Fac Vet Med, El Tagneed St 114, Zagazig 44511, Egypt
[3] Tech Univ Munich, Sch Life Sci Weihenstephan, Reprod Biotechnol, Liesel Beckmann Str 1, D-85354 Freising Weihenstephan, Germany
[4] ProBioGen AG, Herbert Bayer Str 8, D-13086 Berlin, Germany
关键词
WEB TOOL; GENERATION; CHOPCHOP; BACTERIA; SEQUENCE;
D O I
10.1038/s41598-020-67951-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Marek's disease virus (MDV) is a highly cell-associated alphaherpesvirus that causes deadly lymphomas in chickens. While vaccination protects against clinical symptoms, MDV field strains can still circulate in vaccinated flocks and continuously evolve towards greater virulence. MDV vaccines do not provide sterilizing immunity, allowing the virus to overcome vaccine protection, and has increased the need for more potent vaccines or alternative interventions. In this study, we addressed if the CRISPR/Cas9 system can protect cells from MDV replication. We first screened a number of guide RNAs (gRNAs) targeting essential MDV genes for their ability to prevent virus replication. Single gRNAs significantly inhibited virus replication, but could result in the emergence of escape mutants. Strikingly, combining two or more gRNAs completely abrogated virus replication and no escape mutants were observed upon serial passaging. Our study provides the first proof-of-concept, demonstrating that the CRISPR/Cas9 system can be efficiently used to block MDV replication. The presented findings lay the foundation for future research to completely protect chickens from this deadly pathogen.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] What is CRISPR/Cas9?
    Redman, Melody
    King, Andrew
    Watson, Caroline
    King, David
    ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION, 2016, 101 (04): : 213 - 215
  • [32] The CRISPR/CAS9 world
    Perini, Giovanni
    MOLECULAR CYTOGENETICS, 2017, 10
  • [33] Therapeutic and mechanistic insights into Alzheimer's disease using CRISPR/Cas9 technology.
    Sun, Jichao
    Aulston, Brent
    Branes, Kristen
    Roy, Subhojit
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2020, 79 (06): : 686 - 687
  • [34] CRISPR/Cas9 Inducible Systems for Neurodegenerative Disease
    Asmus, Natalie
    Kantor, Boris
    MOLECULAR THERAPY, 2021, 29 (04) : 415 - 415
  • [35] CRISPR/CAS9 Technologies
    Williams, Bart O.
    Warman, Matthew L.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (05) : 883 - 888
  • [36] Harnessing CRISPR/Cas9 technology in cardiovascular disease
    Rezaei, Hamzeh
    Khadempar, Saedeh
    Farahani, Najmeh
    Hosseingholi, Elaheh Zadeh
    Hayat, Seyed Mohammad Gheibi
    Sathyapalan, Thozhukat
    Sahebkar, Amir Hossein
    TRENDS IN CARDIOVASCULAR MEDICINE, 2020, 30 (02) : 93 - 101
  • [37] CRISPR/Cas9 Editing for Gaucher Disease Modelling
    Pavan, Eleonora
    Ormazabal, Maximiliano
    Peruzzo, Paolo
    Vaena, Emilio
    Rozenfeld, Paula
    Dardis, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [38] In vivo and in vitro disease modeling with CRISPR/Cas9
    Kato, Tomoko
    Takada, Shuji
    BRIEFINGS IN FUNCTIONAL GENOMICS, 2017, 16 (01) : 13 - 24
  • [39] Advances in CRISPR/Cas9
    Zhu, Youmin
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [40] CRISPR/Cas9 in epigenetics studies of health and disease
    Sar, Pranati
    Dalai, Sarat
    REPROGRAMMING THE GENOME: CRISPR-CAS-BASED HUMAN DISEASE THERAPY, 2021, 181 : 309 - 343